Australia's Starpharma rises on distribution deal for nasal spray in HK, Macau

Starpharma Holdings

21/10/2022 01:47

** Shares of Starpharma Holdings  SPL.AX  rise as much as
3.3% to A$0.62, set to mark their best session since Oct. 14, if
gains hold 
    ** The drug developer signs sales and distribution agreement
with unit of China-based Hengan International Group  1044.HK 
for co's nasal spray product Viraleze 
    ** The agreement has an initial 2-year term and covers Hong
Kong and Macau
    ** SPL says launch of Viraleze is expected to occur in two
to three months
    ** Stock down ~55.2% so far this year, as of last close 
 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))